ArticleJournal of family medicine and primary care2020

Cost-utility analysis of Macitentan Vs. Bosentan in pulmonary atrial hypertension.

Marzieh Nosrati et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.